Detected ·
STORM Therapeutics
——
STORM Therapeutics closed a $56M Series C financing to accelerate development of STC-15, their first-in-class oral METTL3 inhibitor for cancer treatment, with the first patient dosed in Phase 2 trials for sarcoma.
- Website
- —
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-04-17 15:13:04 UTC
- Signal ID
- 9483b60d-b010-47e8-9f16-c376cda832fd
As the API returns it
{
"id": "9483b60d-b010-47e8-9f16-c376cda832fd",
"created_at": "2026-04-17T15:13:04.112430Z",
"company_name": "STORM Therapeutics",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/storm-therapeutics",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*STORM Therapeutics closed a $56M Series C financing to accelerate development of STC-15, their first-in-class oral METTL3 inhibitor for cancer treatment, with the first patient dosed in Phase 2 trials for sarcoma.*"
}